Verition Fund Management LLC Increases Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Verition Fund Management LLC raised its position in Hims & Hers Health, Inc. (NYSE:HIMSFree Report) by 30.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 798,660 shares of the company’s stock after purchasing an additional 188,506 shares during the quarter. Verition Fund Management LLC’s holdings in Hims & Hers Health were worth $7,108,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at $48,000. Belpointe Asset Management LLC acquired a new position in Hims & Hers Health during the 3rd quarter worth $76,000. EMC Capital Management grew its stake in Hims & Hers Health by 80.0% during the 3rd quarter. EMC Capital Management now owns 12,000 shares of the company’s stock worth $79,000 after purchasing an additional 5,332 shares in the last quarter. Certuity LLC acquired a new position in Hims & Hers Health during the 4th quarter worth $109,000. Finally, Corton Capital Inc. acquired a new position in Hims & Hers Health during the 3rd quarter worth $122,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Oluyemi Okupe sold 98,635 shares of the company’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $21.42, for a total value of $2,112,761.70. Following the sale, the chief financial officer now owns 146,839 shares in the company, valued at approximately $3,145,291.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Hims & Hers Health news, insider Soleil Boughton sold 63,621 shares of the stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $15.17, for a total transaction of $965,130.57. Following the sale, the insider now owns 154,345 shares in the company, valued at approximately $2,341,413.65. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Oluyemi Okupe sold 98,635 shares of the stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $21.42, for a total value of $2,112,761.70. Following the sale, the chief financial officer now owns 146,839 shares in the company, valued at approximately $3,145,291.38. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,014,625 shares of company stock worth $17,153,952. Company insiders own 17.71% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on HIMS shares. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a research note on Tuesday, May 7th. Leerink Partnrs reissued a “market perform” rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Jefferies Financial Group reaffirmed a “hold” rating and set a $15.00 price objective (down from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Finally, Imperial Capital raised Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price objective for the company in a research report on Wednesday, February 28th. Seven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.14.

Read Our Latest Report on Hims & Hers Health

Hims & Hers Health Stock Up 4.0 %

HIMS opened at $21.62 on Tuesday. The business has a 50 day moving average price of $15.10 and a two-hundred day moving average price of $12.16. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $22.10.

Hims & Hers Health (NYSE:HIMSGet Free Report) last released its earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company had revenue of $278.20 million for the quarter, compared to analysts’ expectations of $270.37 million. During the same quarter in the previous year, the firm posted ($0.05) EPS. The firm’s quarterly revenue was up 45.8% on a year-over-year basis. As a group, equities analysts expect that Hims & Hers Health, Inc. will post 0.18 EPS for the current fiscal year.

Hims & Hers Health Profile

(Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Recommended Stories

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMSFree Report).

Institutional Ownership by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.